Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06375044 · ClinicalTrials.gov registry record · Phase 1
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 1 study of Relapsed or Refractory Multiple Myeloma, sponsored by Jiangsu Simcere Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 11
- Study locations
NCT06375044 is a Phase 1 study of Relapsed or Refractory Multiple Myeloma that is actively recruiting participants, run by Jiangsu Simcere Pharmaceutical Co.. The registered enrollment target is 130 participants, below the 329-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (60% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT06375044, a Phase 1 study of Relapsed or Refractory Multiple Myeloma, is actively recruiting participants, sponsored by Jiangsu Simcere Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 11
- Study locations
Study Summary
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial.
Conditions Studied
Interventions
- DRUG SIM0500
Study Locations (11)
New York
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health - New York
- Icahn School of Medicine at Mount Sinai，The Tisch Cancer Institute - New York
Arizona
- Mayo Clinic Arizona - Phoenix
Florida
- Mayo Clinic Florida - Jacksonville
Massachusetts
- Dana Farber Cancer institution - Boston
Minnesota
- Mayo Clinic Rochester - Rochester
Beijing Municipality
- Beijing Chaoyang Hospital Capital Medical University - Beijing
Guangdong
- Sun Yat-sen University Cancer Center - Guangzhou
Henan
- Henan Cancer Hospital - Zhengzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2024-05-24 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06375044
The ClinicalTrials.gov registry entry for NCT06375044 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 329-participant average among 10 other Relapsed or Refractory Multiple Myeloma trials with a reported enrollment target (60% lower). The listed sponsor is Jiangsu Simcere Pharmaceutical Co., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which SIM0500 is the first listed.
NCT06375044 reports 11 study locations spanning 10 distinct geographic areas - top geographies include New York, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06375044 about?
NCT06375044 is a clinical study titled "Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma". This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimi...
What is the current status of trial NCT06375044?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2024-05-24. Estimated completion is 2028-12-30.
What conditions does trial NCT06375044 study?
This clinical trial studies the following conditions: Relapsed or Refractory Multiple Myeloma.
What interventions are being tested in trial NCT06375044?
The interventions under investigation include: SIM0500 (DRUG).
Who is sponsoring clinical trial NCT06375044?
This trial is sponsored by Jiangsu Simcere Pharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06375044 being conducted?
This trial has 11 study locations across Arizona, Florida, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RECRUITING · Phase 1
-
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 1
-
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
COMPLETED · Phase 1
-
Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients
COMPLETED · Phase 1
-
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.